Compare Berkshire Hathaway Inc Class B (BRK.B) vs Pfizer Inc (PFE) Price & Performance

Berkshire Hathaway Class B shares (BRK.B) trade at $489.92, down 1.38% today, with a bullish technical signal driven by moving averages. Analyst consensus is positive with 57% buy ratings. The stock's fundamentals reflect Berkshire's diversified holdings and strong cash flow, though key valuation ratios are not provided in the current dataset.

The outlook remains favorable given institutional support and bullish technicals, but risks include market volatility and reliance on broad economic health. Upside potential hinges on continued operational performance across its subsidiaries and strategic capital allocation by management.

Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.

The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.